ArticleNature2025
In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.Nature reviews. Clinical oncology · 2026Review
- Article
- Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.Journal for immunotherapy of cancer · 2026Article
- Metabolic profiling of CAR T-cells in patients reveals a shift toward amino acid-supported OXPHOS and informs transporter engineering.Research square · 2026Article
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- On-target and off-target activities of CRISPR therapeutics across scales.Trends in biotechnology · 2026Review
- CRISPR application in hematological disorders: from bench to bedside.Blood advances · 2026Review
- The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells.The Journal of experimental medicine · 2026Article
- Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy.Biomarker research · 2026Review
- High-Precision Intrinsic Interactome Elucidation of Chimeric Antigen Receptors via Photocatalytic Micromapping (μMap-CAR).Journal of the American Chemical Society · 2026Article
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Segmentation-free analysis of live-cell imaging data reveals how T cell modifications influence cancer cell aggregation dynamics.Scientific reports · 2026Article
- Single-cell genomics links targeted functional manipulations to efficacy-associated chromatin signatures in CAR T cells.Research square · 2026Article
- Peptide-MHC-targeted engineered virus-like particles enable selective priming and gene editing of tumor-specific T cells.Cell reports · 2026Article
- The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects.Signal transduction and targeted therapy · 2026Review
- A community machine learning challenge to predict the effects of gene perturbations on T cell differentiation for cancer immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Parallel Activation and Interference CRISPR (PAIR) with Sequencing Uncovers DNA Repair Networks Guiding Precision Cell Engineering.bioRxiv : the preprint server for biology · 2026Article
- In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Design principles of the cytotoxic CD8Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Progress in cell-based immunotherapies for solid tumors.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Nelson H Knudsen *Krantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Giulia Escobar *Krantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.ORCID 0000-0001-9177-0251
Felix Korell *Krantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Tamina KienkaKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Celeste NobregaBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA.
Seth AndersonBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA.
Andrew Y ChengBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA.
Maria ZschummelBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-4778-8742
Alexander ArmstrongKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.ORCID 0009-0003-6957-9903
Amanda BouffardKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Michael C KannKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Sadie GoncalvesKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Hans W PopeBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA.
Mitra PezeshkiBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA.
Alexander RojasBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA.
Juliette S M T SuermondtBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA.
Merle PhillipsKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Trisha R BergerKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Sangwoo ParkKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.ORCID 0000-0002-2701-3114
Diego Salas-BenitoKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Elijah P DarnellKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Filippo BirocchiKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Mark B LeickKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.ORCID 0000-0003-3111-0221
Rebecca C LarsonKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
John G DoenchBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-3707-9889
Debattama SenKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.ORCID 0000-0002-0947-8284
Kathleen B YatesBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-7383-5573
Robert T MangusoKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. rmanguso@broadinstitute.org.ORCID 0000-0003-1336-413X
Marcela V MausKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. mvmaus@mgh.harvard.edu.ORCID 0000-0002-7578-0393
Funding
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7MOvercoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodiesR01CA238268 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Marcela Valderrama Maus · 2019 to 2026
$4.0MNCI NIH HHS R01 CA238268NIGMS NIH HHS T32 GM144273
Abstract
Chimeric antigen receptor (CAR) T cells are highly effective in haematological malignancies
Indexed as
Clustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsImmunotherapy, AdoptiveMultiple MyelomaReceptors, Chimeric AntigenT-LymphocytesAnimalsB-Cell Maturation AntigenCell Line, TumorCell ProliferationFemaleHumansMaleMiceB-Cell Maturation AntigenReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.